


Claims

1. Utilization of at least one highly fluorinated alkan of the general formula



where


R_F is a linear or branched perfluorinated alkyl chain C_2F_5 to $\text{C}_{12}\text{F}_{23}$,

R_1 and R_2 are independently selected from the group H, CH_3 , C_2H_5 and C_3H_7 ,

n is selected from the numbers 0, 1 and 2, and

x is a number between 2 and 6,

where a compound of the formula



with the said meanings and with a molecular weight of at least 750 was reacted with a radical initiator to a degree of oligomerization of 2 to 6 to produce the highly fluorinated oligomeric alkane, as a treatment agent in an ophthalmology or pharmacological preparations for ophthalmology.

2. Utilization as in Claim 1 as a vitreous body substitute and/or for retinal tamponade.
3. Utilization as in Claim 1 as a liquid implant.
4. Utilization as in Claim 1 as a tear substitute.
5. Utilization as in Claim 1 as a carrier substance for pharmacological agents that are to be introduced.
6. Utilization as in one of the preceding claims, which is characterized by the fact that the treatment agent contains several of the said highly fluorinated oligomeric alkans that are different from each other.
7. Utilization as in one of the preceding claims, which is characterized by the fact that the oligomeric alkan is used as a component of pharmacological preparations for ophthalmology and with that in mixtures.